These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1782484)

  • 1. Human plasma fractionation and the impact of new technologies on the use and quality of plasma-derived products.
    Brodniewicz-Proba T
    Blood Rev; 1991 Dec; 5(4):245-57. PubMed ID: 1782484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
    Farrugia A
    Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma fractionation in blood transfusion service.
    Haskó F; Salamon M; Bartha K; Dobó P
    Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of chromatography to manufacture purer and safer plasma products.
    Johnston A; Adcock W
    Biotechnol Genet Eng Rev; 2000; 17():37-70. PubMed ID: 11255674
    [No Abstract]   [Full Text] [Related]  

  • 5. What can be learned in the snake antivenom field from the developments in human plasma derived products?
    Burnouf T
    Toxicon; 2018 May; 146():77-86. PubMed ID: 29621528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood products.
    Med Lett Drugs Ther; 1979 Nov; 21(23):93-6. PubMed ID: 502967
    [No Abstract]   [Full Text] [Related]  

  • 7. The current status of blood fractionation in the United States.
    Sgouris JT
    Vox Sang; 1972; 23(1):45-55. PubMed ID: 5081014
    [No Abstract]   [Full Text] [Related]  

  • 8. Polychlorinated biphenyls and organochlorine pesticides are eliminated from therapeutic Factor VIII and immunoglobulin concentrates and reduced in albumin by plasma fractionation.
    Covaci A; Laub R; Di Giambattista M; Branckaert T; Hougardy V; Schepens P
    Vox Sang; 2002 Jul; 83(1):23-8. PubMed ID: 12100385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges for new haemophilia products from a manufacturer's perspective.
    Schulte S
    Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved utilization of blood due to systematic fractionation.
    Högman CF
    Qual Assur Health Care; 1990; 2(3-4):207-12. PubMed ID: 1983239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.
    Allersma DP; Roeffen E; Van der Does JA; Briët E
    Pharm Weekbl Sci; 1991 Feb; 13(1):18-23. PubMed ID: 1903526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-pool high-yield factor VIII production.
    Smit Sibinga CT
    Crit Rev Clin Lab Sci; 1986; 24(1):43-70. PubMed ID: 3098500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apheresis.
    Nilsson IM; Freiburghaus C
    Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality evaluation of human serum albumin prepared by heat denaturation in Iran: an experience for developing countries.
    Khorsand Mohammad Pour H; Banazadeh S; Aghaie A
    Transfus Apher Sci; 2014 Apr; 50(2):219-24. PubMed ID: 24525282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of Plasma Fractionation in Biological Medicines Production.
    Mousavi Hosseini K; Ghasemzadeh M
    Iran J Biotechnol; 2016 Dec; 14(4):213-220. PubMed ID: 28959338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
    Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate.
    Farrugia A; Spiers D; Young I; Oates A; Herrington R; Damianos F
    Vox Sang; 1989; 57(1):4-9. PubMed ID: 2800464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.